No spam - just the good stuff

Subscribe to our newsletter

News

Biotech

Vincere lands grant funding for research into mitophagy enhancing Parkinson’s drug

Genflow makes progress towards clinical trial of NASH gene therapy

Standing at the precipice of a biotech renaissance – the confluence of AI and SynBio

The coming together of two of the most transformative technologies of our age will shine a light on our manipulation of biological systems.

The quest for rejuvenation without reprogramming

Nine Square Therapeutics lands $4.5m to advance development of novel Parkin activators

Rejuveron lands $75m to advance healthy aging portfolio; expands focus in Middle East

Alnylam drug shown to reduce blood pressure in Phase 2 trial

Telomere-boosting mRNA therapeutic turns back the aging clock

Rejuvenation Technologies exits stealth with $10.6m for age-reversing mRNA therapeutics

Hyperbaric oxygen therapy – a patient’s perspective

Young blood rising: new plasma therapy moves closer to the clinic

Clock.bio launches to decode rejuvenation biology across human genome

AgeX to merge with Serina Therapeutics

BlueRock’s cell therapy shows early promise in Parkinson’s study

Do long-lived flies hold the key to extending human longevity?

Neuronascent lands NIA grant to advance Alzheimer’s treatment to Phase 2 clinical trials

Mitrix presents mitochondrial bioreactor technology at Longevity Summit Dublin

Vaxxinity publishes positive results in Alzheimer’s trial

Powering precision medicine with proteomics

Novel approach can engineer blood vessels

Rejuvenate Biomed publishes promising sarcopenia data for metformin and galantamine combination

Finding the recipe for success in cell therapy

MyMD reports positive results in Phase 2 sarcopenia trial

Protein-targeting vaccine signposts Alzheimer’s breakthrough

FOXO Technologies launches bioinformatics services and hopes to revolutionize epigenetic data analysis

Focal Biosciences: new cellular reprogramming startup unveiled

Biophytis applies to commence “first ever” Phase 3 sarcopenia trial

Skyline gets green light for AMD gene therapy trial

Insilico doses first patients in Phase 2 IPF trial

Cognition Therapeutics reports positive Alzheimer’s clinical trial results

Celmatix identifies leads in oral fertility drug program

Verge reports positive clinical trial results for AI-discovered ALS drug

Find us here ...

Subscribe to our newsletter

© Copyright 2023 FIRST LONGEVITY Limited. All rights reserved. FIRST LONGEVITY

The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding a knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

DISCLAIMER FOR U.S. BASED INVESTORS

The Agent of First Longevity Limited in the United States is Marco Polo Securities Inc, a non-affiliated broker-dealer registered with the US Securities and Exchange Commission. The activities of First Longevity Limited in the United States will be affected only to the extent permitted by Rule 15a-6 under the US Securities Exchange Act of 1934 and in accordance with the Services Agreement entered into between First Longevity Limited and Marco Polo Securities Inc with respect thereto. Contact at Marco Polo Securities is clientservices@mpsecurities.com; 1-347-745-6448.